MLC追踪与门控作为前列腺SABR分次内运动适应策略的比较:TROG 15.01 SPARK试验分析
结果显示两种策略均优于无运动适应,两者间剂量差异很小,但门控导致治疗中断。
要点
- MLC追踪与门控均使递送剂量更接近计划,优于无运动适应策略。
- 两种策略间剂量学差异小,平均差异在-0.3%至1.4%之间。
- 门控每分次平均需0.5次床移位,平均中断1.8±2.6分钟。
核心结论
- MLC追踪和门控均能有效提高靶区与危及器官的剂量递送准确性。
- 两者剂量学性能相当,但门控会导致治疗中断。
研究设计与样本
- 采用时间分辨运动编码剂量重建方法评估递送剂量并与无运动适应估计比较。
主要发现
- MLC追踪和门控递送剂量均比无运动适应策略更接近计划。
- MLC追踪与门控间平均计划差异为-0.3%(CTV D98%)、1.4%(CTV D2%)、0.4%(PTV D95%)、0.2%(直肠V30Gy)、0.0%(膀胱V30Gy)。
- 门控分次平均需0.5次床移位,每分次平均中断持续时间1.8±2.6分钟。
关键数值与推荐
- MLC追踪与门控间平均计划差异:CTV D98%为-0.3%,CTV D2%为1.4%,PTV D95%为0.4%,直肠V30Gy为0.2%,膀胱V30Gy为0.0%。
临床怎么用
- 前列腺SABR中可选择MLC追踪或门控作为实时运动适应策略,两者剂量学性能相当。
- 选择门控时需考虑治疗中断及床移位带来的时间成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic Ablative Radiotherapy (SABR) has recently emerged as a favourable treatment option for prostate cancer patients. With higher doses delivered over fewer fractions, motion adaptation is a requirement for accurate delivery of SABR. This study compared the efficacy of multileaf collimator (MLC) tracking vs. gating as a real-time motion adaptation strategy for prostate SABR patients enrolled in a clinical trial. METHODS: Forty-four prostate cancer patients treated over five fractions in the TROG 15.01 SPARK trial were analysed in this study. Forty-nine fractions were treated using MLC tracking and 166 fractions were treated using beam gating and couch shifts. A time-resolved motion-encoded dose reconstruction method was used to evaluate the dose delivered using each motion adaptation strategy and compared to an estimation of what would have been delivered with no motion adaptation strategy implemented. RESULTS: MLC tracking and gating both delivered doses closer to the plan compared to when no motion adaptation strategy was used. Differences between MLC tracking and gating were small with differences in the mean discrepancy from the plan of -0.3% (CTV D98%), 1.4% (CTV D2%), 0.4% (PTV D95%), 0.2% (rectum V30Gy) and 0.0% (bladder V30Gy). On average, 0.5 couch shifts were required per gated fractions with a mean interruption duration of 1.8 ± 2.6 min per fraction treated using gating. CONCLUSION: Both MLC tracking and gating were effective strategies at improving the accuracy of the dose delivered to the target and organs at risk. While dosimetric performance was comparable, gating resulted in interruptions to treatment. CLINICAL TRIAL REGISTRATION NUMBER: NCT02397317.
引用
- Hewson EA, Nguyen DT, O'Brien R, et al. Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial. Radiother Oncol. 2020. PMID: 32828839. doi:10.1016/j.radonc.2020.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。